Sensus Healthcare (SRTS) Set to Announce Quarterly Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Sensus Healthcare to post earnings of ($0.04) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.14. The company had revenue of $12.57 million for the quarter, compared to the consensus estimate of $12.10 million. Sensus Healthcare had a return on equity of 1.04% and a net margin of 1.99%.

Sensus Healthcare Trading Up 6.9 %

Shares of NASDAQ:SRTS traded up $0.25 during mid-day trading on Thursday, reaching $3.86. The stock had a trading volume of 176,260 shares, compared to its average volume of 142,837. The company has a market cap of $63.27 million, a P/E ratio of 129.04 and a beta of 0.92. Sensus Healthcare has a 1 year low of $1.79 and a 1 year high of $5.38. The business's 50 day moving average price is $3.72 and its 200 day moving average price is $3.07.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.